Section 1: Abstract Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by amyloid plaques and neurofibrillary tangles. As the most common cause of dementia, AD affects 1 in 9 Americans aged 65 and older and was the seventh leading cause of death in the United States in 2021. While deaths from stroke and heart disease decreased from 2000 to 2021, deaths from AD increased more than 140% during this period, and AD is projected to affect 13.8 million Americans by 2060 (figure 1). Given that AD begins 20 years or more before symptom onset, there is a substantial window in which medical interventions may alter the disease progression. By 2050, the number of individuals affected by AD is projected to surpass 150 million, yet effective therapeutic interventions to halt or reverse the disease remain elusive. [1,2]
